在前列腺癌中,MED12和CDK8/19调节雄激素受体活性和酶胺反应
Chiara Andolfi1, Caterina Bartolini1,2, Elisa Morales1,3
1Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Endocrinology
|September 10, 2024
概括
抑制MED12和CDK8/19可以降低前列腺癌细胞的增殖和AR活性. 这些因素可能会改善对恩扎拉胺治疗的反应,为治疗晚期前列腺癌提供新的途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因规则 基因规则
背景情况:
- 前列腺癌的进展依赖于雄激素受体 (AR) 活性.
- 作为AR抑制剂的恩扎胺提高了生存率,但耐药性,通常通过AR-V7,限制了疗效.
- 包括MED12和CDK8/19在内的调解者复合体影响细胞增殖和基因表达.
研究的目的:
- 研究MED12和CDK8/19在前列腺癌细胞系中的作用.
- 为了确定它们对雄激素受体 (AR) 活性和对恩扎胺的反应的影响.
- 探索针对这些组件的潜在治疗策略.
主要方法:
- 在LNCaP,22Rv1和PC3前列腺癌细胞系中抑制MED12表达和CDK8/19活性.
- 对细胞增殖,AR活性,PSA分泌和AR基因表达的评估.
- 评估使用MED12/CDK8/19抑制剂和恩扎胺的联合治疗方法.
主要成果:
- 在所有测试的细胞系中,MED12和CDK8/19的抑制降低了细胞的增殖.
- 抑制MED12降低了c-Myc表达和AR信号,包括抗性细胞中的AR-V7表达.
- 与恩扎胺的联合抑制显示了减少AR活性和扩散的附加效应.
结论:
- MED12和CDK8/19是前列腺癌中AR活性的关键调节剂.
- 针对MED12和CDK8/19可以克服恩扎胺耐药性.
- 这些发现表明,对于晚期前列腺癌,有新的治疗策略.
更多相关视频
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K